Correlation of fibroblast growth factor 21 serum levels with metabolic parameters in Japanese subjects

Journal of Medical Investigation

Volumn 61, Issue 1-2, 2014, Pages 28-34

  Jin, Qing Ri ^a   Bando, Yukiko ^b   Miyawaki, Katsuyuki ^a   Shikama, Yosuke ^b   Kosugi, Chisato ^b   Aki, Nanako ^a,b   Funaki, Makoto ^b   Noji, Sumihare ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Biomarker; FGF21; Metabolic syndrome; Systolic BP; Triglycerides

Indexed keywords

BIOLOGICAL MARKER; CHOLESTEROL; FIBROBLAST GROWTH FACTOR 21; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; FIBROBLAST GROWTH FACTOR; GLUCOSE BLOOD LEVEL;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC ASSOCIATION; GLUCOSE BLOOD LEVEL; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; PULSE PRESSURE; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD; BLOOD PRESSURE; COMPARATIVE STUDY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CROSS-SECTIONAL STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 84897931588     PISSN: 13431420     EISSN: 13496867     Source Type: Journal    
DOI: 10.2152/jmi.61.28     Document Type: Article

References (28)

1. Nishimura T, Nakatake Y, Konishi M, Itoh N: Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206, 2000
2. Kharitonenkov A, Larsen P: FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab 22: 81-86, 2011
3. Itoh N: Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 342: 1-11, 2010
4. Reiche M, Bachmann A, Lossner U, Bluher M, Stumvoll M, Fasshauer M: Fibroblast growth factor 19 serum levels: relation to renal function and metabolic parameters. Horm Metab Res 42: 178-181, 2010
5. Schreuder TC, Marsman HA, Lenicek M, van Werven JR, Nederveen AJ, Jansen PL, Schaap FG: The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am J Physiol Gastrointest Liver Physiol 298: G440-445, 2010
6. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y: FGF-23 in patients with endstage renal disease on hemodialysis: Kidney Int 65: 1943-1946, 2004
7. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers: Kidney Int 64: 2272-2279, 2003
8. Li H, Fang Q, Gao F, Fan J, Zhou J, Wang X, Zhang H, Pan X, Bao Y, Xiang K, Xu A, Jia W: Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 53: 934-940, 2010
9. Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F, Wong RL, Chow WS, Tso AW, Lam KS, Xu A: Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57: 1246-1253, 2008
10. Chen WW, Li L, Yang GY, Li K, Qi XY, Zhu W, Tang Y, Liu H, Boden G: Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 116: 65-68, 2008
11. Mraz M, Bartlova M, Lacinova Z, Michalsky D, Kasalicky M, Haluzikova D, Matoulek M, Dostalova I, Humenanska V, Haluzik M: Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 71: 369-375, 2009
12. Durovcova V, Marek J, Hana V, Matoulek M, Zikan V, Haluzikova D, Kaválková P, Lacinová Z, Krsek M, Haluzík M: Plasma concentrations of fibroblast growth factors 21 and 19 in patients with Cushing's syndrome. Physiol Res 59: 415-422, 2010
13. Dostalova I, Kavalkova P, Haluzikova D, Lacinova Z, Mraz M, Papezova H, Haluzík M: Plasma concentrations of fibroblast growth factors 19 and 21 in patients with anorexia nervosa. J Clin Endocrinol Metab 93: 3627-3632, 2008
14. Xiao Y, Xu A, Law LS, Chen C, Li H, Li X, Yang L, Liu S, Zhou Z, Lam KS: Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. J Clin Endocrinol Metab 97: E54-58, 2012
15. Eto K, Tumenbayar B, Nagashima S, Tazoe F, Miyamoto M, Takahashi M, Ando A, Okada K, Yagyu H, Ishibashi S: Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes. Diabetes Res Clin Pract 89: 52-57, 2010
16. Chen C, Cheung BM, Tso AW, Wang Y, Law LS, Ong KL, Wat NM, Xu A, Lam KS: High plasma level of fibroblast growth factor 21 is an Independent predictor of type 2 diabetes: a 5.4-year population-based prospective study in Chinese subjects. Diabetes Care 34: 2113-2115, 2011
17. Alberti KG, Zimmet P, Shaw J: Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23: 469-480, 2006
18. Ministry of Health, Labour and welfare of Japan. Diichi publishing Co., Tokyo. The National Health and Nutrition Survey in Japan (in Japanese): 2003, 2006
19. Division of Health Promotion, Tokushima Prefectural Office, The Prefectural Health and Nutrition Survey in Tokushima (in Japanese): 2003, 2004
20. Sheldon G, Henry R, Jerome D, Norman M, Keith C: The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157: 2413-2446, 1997
21. Fuster V, Gotto AM, Libby P, Loscalzo J, McGill HC: 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. J Am Coll Cardiol 27: 964-976, 1996
22. Lu Y, Liu JH, Zhang LK, Du J, Zeng XJ, Hao G, Huang J, Zhao DH, Wang GZ, Zhang YC: Fibroblast growth factor 21 as a possible endogenous factor inhibits apoptosis in cardiac endothelial cells. Chin Med J (Engl) 123: 3417-3421, 2010
23. Lin Z, Wu Z, Yin X, Liu Y, Yan X, Lin S, Xiao J, Wang X, Feng W, Li X: Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile. PLoS One 5: e15534, 2010
24. Okada K, Iso H, Cui R, Inoue M, Tsugane S: Pulse pressure is an independent risk factor for stroke among middle-aged Japanese with normal systolic blood pressure: the JPHC study. J Hypertens 29: 319-324, 2011
25. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Hawkins ED, Wroblewski VJ, Li DS, Mehrbod F, Jaskunas SR, Shanafelt AB: FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635, 2005
26. Kharitonenkov A, Shanafelt AB: Fibroblast growth factor-21 as a therapeutic agent for metabolic diseases. BioDrugs 22: 37-44, 2008
27. Eto K: FGF-21, a newcomer in the field of hypertension research. J Hum Hypertens 27: 343-344, 2013
28. Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA: Fibroblast growth factor-21 regulates PPARg activity and the antidiabetic actions of thiazolidinediones. cell 148: 556-567, 2012